Tax & PenaltyJul 9, 2026, 06:08 AM
Alterity Therapeutics Receives A$3.98M R&D Tax Incentive
AI Summary
Alterity Therapeutics announced it has received an A$3.98 million research and development (R&D) tax refund for the 2025 financial year. This refund, which includes A$43,117 in interest, is provided under the Australian Government's R&D tax incentive program. The company plans to use these funds to support the ongoing development of its clinical programs, particularly its lead asset ATH434 for neurodegenerative diseases.
Key Highlights
- Received A$3,982,992 R&D tax refund for the 2025 financial year.
- Refund includes A$43,117 in interest.
- The refund is part of the Australian Government's R&D tax incentive program.
- The incentive provides a refundable tax offset of up to 43.5%.
- Funds will be used for continued development of Alterity's clinical programs.
Price Impact
More from ATHE